MetaStat Appoints Richard J. Berman and H. Philip Goodeve to Board of Directors
2014年10月21日 - 9:55PM
ビジネスワイヤ（英語）
Decades of Experience Add Strength to Board
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company
focused on understanding and treating systemic metastasis,
appointed Richard J. Berman and H. Philip Goodeve to its Board of
Directors, effective October 15. Mr. Berman and Mr. Goodeve replace
Warren Lau and Dr. Patrick Mooney, both of whom have resigned from
the Board. In addition, Johan M. (Thijs) Spoor has resigned as
Chairman of the Board while remaining a Board member.
Mr. Berman will serve as lead independent director and Chairman
of the Company’s Nominating and Corporate Governance Committee, as
well as a member of the Company’s Compensation Committee. His
business career spans more than 35 years of venture capital, senior
management and merger and acquisitions experience. In the past five
years, he has served as a director and/or officer of more than a
dozen public and private companies. From 2006 to 2011, he was
Chairman of National Investment Managers, a company with $12
billion in pension administration assets. He held previous
positions at companies including NexMed Inc., Easy Link Int’l.,
Goldman Sachs and Bankers Trust Company. He obtained bachelor of
science and M.B.A. degrees from Stern School of Business at New
York University and U.S. and foreign law degrees from Boston
College and The Hague Academy of International Law,
respectively.
Mr. Berman said, “Over the course of my career, which includes
extensive experience within the life science sector, I have come to
understand and appreciate the importance of innovation within
oncology, including the creation of new and more informative
diagnostic tests. I believe that the tests developed to date by
MetaStat represent the best kind of this type of innovation, and I
look forward to helping guide the Company as we prepare for
commercialization.”
Mr. Goodeve will serve as a member of the Company’s Compensation
Committee and Audit Committee. He has more than 25 years of
experience in the global capital markets and has been a corporate
finance consultant since 2009. He has led more than 100 change of
control transactions, 10 IPOs and 15 turnarounds. Most recently, he
was Chief Financial Officer of FINCA International Inc., one of the
largest microfinance banking groups in the world, with operations
in 21 countries. Among other roles including serving on numerous
other public and private company boards, he was the Global Co-Head
of Financial Services Investment Banking for CIBC Capital Markets.
He obtained a bachelor and commerce, accounting degree from Queen’s
University and an M.B.A. from Harvard Business School.
Mr. Goodeve said, “The challenges for small publicly traded
companies in healthcare include attracting the necessary funding
while conveying the importance of new technologies. At MetaStat, I
intend to harness my experience in capital markets to help develop
a strategy that will maximize the Company’s profile. I look forward
to working closely with the MetaStat team as the company evolves to
the next stages of growth and development.”
Oscar L. Bronsther, M.D., Chief Executive Officer of MetaStat,
said, “Richard Berman and Philip Goodeve together bring a
tremendous amount of business and industry experience to MetaStat,
and we are honored to have them serve on our Board. Richard’s
extensive knowledge of our industry, his role in the governance of
publicly held companies and his directorships in other life science
companies qualify him to serve as our director. Philip’s experience
in the global capital markets provides a valuable perspective to
our Board on strategy, competitive industry dynamics and capital
markets transactions. Finally, I would like to thank Warren Lau,
who founded our company and recognized the importance of our core
technology, and Patrick Mooney for their years of service to
MetaStat and we wish them the best in their future endeavors.”
About MetaStat, Inc.
MetaStat, Inc (MTST) is a molecular diagnostic company that
develops and commercializes diagnostic tests for early and reliable
prediction of systemic metastasis, the process by which cancer
spreads from a primary tumor through the bloodstream to other areas
of the body. MetaStat is focused on breast, prostate, lung and
colorectal cancers, where systemic metastasis is responsible for
approximately 90% of all deaths. The Company’s function-based
diagnostic platform technology is based on the identification and
understanding of the pivotal role of the mena protein and its
isoforms, a common pathway for the development of systemic
metastatic disease in all epithelial-based solid tumors. Both the
MetaSite Breast™ and MenaCalc™ assays are designed to accurately
stratify patients based on their individual risk of metastasis and
to provide physicians with clinically actionable information to
better "customize" cancer treatment. MetaStat’s testing platform
improves treatment planning decisions by positively identifying
patients with a high-risk of metastasis who need aggressive therapy
and by sparing patients with a low-risk of metastasis from the
harmful side effects and expense of chemotherapy. The company is
based in Boston.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, and such forward-looking statements are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause
future circumstances, events or results to differ materially from
those projected in the forward-looking statements as a result of
various factors and other risks, including those set forth in the
Company's Form 10-K filed with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and the company undertakes
no obligation to update such statements.
Media:Dian Griesel Int’l. for MetaStatSusan Forman,
212-825-3210sforman@dgicomm.comorInvestor:MetaStat,
Inc.Daniel Schneiderman, 212-608-0827Vice
Presidentdan@metastat.com
MetaStat (CE) (USOTC:MTST)
過去 株価チャート
から 10 2024 まで 11 2024
MetaStat (CE) (USOTC:MTST)
過去 株価チャート
から 11 2023 まで 11 2024
